OBJECTIVES: To use genotype analysis to determine the prevalence of the c.1436C→T sequence variant in carnitine palmitoyltransferase 1A (CPT1A) among Alaskan infants, and evaluate the sensitivity of newborn screening by tandem mass spectrometry (MS/MS) to identify homozygous infants. STUDY DESIGN: We compared MS/MS and DNA analyses of 2409 newborn blood spots collected over 3 consecutive months. RESULTS: Of 2409 infants, 166 (6.9%) were homozygous for the variant, all but one of whom were of Alaska Native race. None of the homozygous infants was identified by MS/MS on the first newborn screen using a C0/C16 + C18 cutoff of 130. Among 633 Alaska Native infants, 165 (26.1%) were homozygous and 218 (34.4%) were heterozygous for the variant. The prevalence was highest in Alaska's northern/western regions (51.2% of 255 infants homozygous; allele frequency, 0.7). CONCLUSIONS: The CPT1A c.1436C→T variant is prevalent among some Alaska Native peoples, but newborn screening using current MS/MS cutoffs is not an effective means to identify homozygous infants. The clinical consequences of the partial CPT1A deficiency associated with this variant are unknown. If effects are substantial, revision of newborn screening, including Alaska-specific MS/MS cutoffs and confirmatory genotyping, may be needed.
OBJECTIVES: To use genotype analysis to determine the prevalence of the c.1436C→T sequence variant in carnitine palmitoyltransferase 1A (CPT1A) among Alaskan infants, and evaluate the sensitivity of newborn screening by tandem mass spectrometry (MS/MS) to identify homozygous infants. STUDY DESIGN: We compared MS/MS and DNA analyses of 2409 newborn blood spots collected over 3 consecutive months. RESULTS: Of 2409 infants, 166 (6.9%) were homozygous for the variant, all but one of whom were of Alaska Native race. None of the homozygous infants was identified by MS/MS on the first newborn screen using a C0/C16 + C18 cutoff of 130. Among 633 Alaska Native infants, 165 (26.1%) were homozygous and 218 (34.4%) were heterozygous for the variant. The prevalence was highest in Alaska's northern/western regions (51.2% of 255 infants homozygous; allele frequency, 0.7). CONCLUSIONS: The CPT1A c.1436C→T variant is prevalent among some Alaska Native peoples, but newborn screening using current MS/MS cutoffs is not an effective means to identify homozygous infants. The clinical consequences of the partial CPT1Adeficiency associated with this variant are unknown. If effects are substantial, revision of newborn screening, including Alaska-specific MS/MS cutoffs and confirmatory genotyping, may be needed.
Authors: Melanie B Gillingham; Matthew Hirschfeld; Sarah Lowe; Dietrich Matern; James Shoemaker; William E Lambert; David M Koeller Journal: Mol Genet Metab Date: 2011-06-28 Impact factor: 4.797
Authors: Dominick J Lemas; Howard W Wiener; Diane M O'Brien; Scarlett Hopkins; Kimber L Stanhope; Peter J Havel; David B Allison; Jose R Fernandez; Hemant K Tiwari; Bert B Boyer Journal: J Lipid Res Date: 2011-11-01 Impact factor: 5.922
Authors: Sirui Zhou; Lan Xiong; Pingxing Xie; Amirthagowri Ambalavanan; Cynthia V Bourassa; Alexandre Dionne-Laporte; Dan Spiegelman; Maude Turcotte Gauthier; Edouard Henrion; Ousmane Diallo; Patrick A Dion; Guy A Rouleau Journal: PLoS One Date: 2015-05-26 Impact factor: 3.240
Authors: Suzan J G Knottnerus; Jeannette C Bleeker; Rob C I Wüst; Sacha Ferdinandusse; Lodewijk IJlst; Frits A Wijburg; Ronald J A Wanders; Gepke Visser; Riekelt H Houtkooper Journal: Rev Endocr Metab Disord Date: 2018-03 Impact factor: 6.514
Authors: David M Koeller; Matt Hirschfeld; Stephanie Birch; Thalia Wood; Rebekah Morisse; Sabra Anckner; Bradford D Gessner Journal: Genet Med Date: 2017-08-03 Impact factor: 8.822
Authors: Bradford D Gessner; Thalia Wood; Monique A Johnson; Carolyn Sue Richards; David M Koeller Journal: Genet Med Date: 2016-01-28 Impact factor: 8.822